FGFR1 Amplification in ER+ Breast Cancer
A guide to the driver layer of FGFR1 amplification in ER-positive breast cancer, including endocrine resistance, ctDNA fluctuation, and what is or is not targetable today
FGFR1 amplification is one of the clearest bypass pathways in ER-positive, HER2-negative breast cancer.
It shows up most often in more aggressive luminal-B-like disease.
What FGFR1 amplification means
FGFR1 stands for fibroblast growth factor receptor 1.
It is a cell-surface receptor that receives growth signals and then activates downstream pathways such as MAPK/ERK and PI3K/AKT.
When a report says FGFR1 amplification, it means the tumour carries extra copies of the FGFR1 gene.
That extra copy number can increase signalling for:
growth
survival
migration
endocrine resistance
In breast cancer, FGFR1 amplification is reported in roughly 7.5% to 17% of cases overall.
It is enriched in more aggressive ER-positive luminal-B-like tumours.
FGFR1 is a well-described resistance mechanism.
In ER-positive disease, FGFR1 amplification has been associated with:
earlier relapse
weaker response to endocrine therapy
persistence of estrogen-receptor signalling even when estrogen is suppressed
One reason is pathway cross-talk.
FGFR1 can keep survival and proliferation signalling active even when the main endocrine pathway is under pressure.
That helps explain why some ER-positive cancers keep growing despite aromatase inhibition or other endocrine strategies.
Why a Guardant360 FGFR1 result can appear, fade, or disappear
A Guardant360 result reflects circulating tumour DNA in the blood.
It does not sample every tumour cell in the body at the same moment.
That matters more for copy-number signals like FGFR1 amplification than for some simple point mutations.
A strong FGFR1 call on one draw can look weaker later, or disappear from a later report, for a few common reasons:
Lower tumour burden can reduce ctDNA shedding below the reporting threshold.
Clonal shifts can make a different tumour population dominate the blood signal.
Detection cutoffs can move a result from high to low to not reported without proving the biology is gone.
A disappearing ctDNA FGFR1 call does not prove that the tumour permanently reverted.
It also does not mean the earlier call was meaningless.
Most often, it means the currently shedding tumour population is no longer producing a strong enough copy-number signal to be called on that blood draw.
For closely related context, see Blood Biopsy Trial — Getting Ahead of Treatment Resistance.
For cross-subtype context on low shedding and negative blood-test results, see ctDNA and cfDNA in Breast Cancer: What “Low Shedding” Means.
Is FGFR1 targetable today?
Biologically, yes.
In routine breast-cancer care, not yet in the same way as ESR1, PIK3CA, HER2, or BRCA-related pathways.
That means two statements can both be true:
there is no routine FGFR1-directed standard of care in breast cancer today
FGFR1 is still a real trial target and a meaningful resistance mechanism
Clinical research has explored:
pan-FGFR inhibitors
FGFR-selective agents
newer FGFR1/2 degraders
combination strategies with endocrine therapy and CDK4/6 inhibition
So FGFR1 is best treated as a research-active target, not a solved clinical target.
Where FGFR1 fits in the EMT and fibrosis axis
FGFR1 is not itself a classic fibrotic factor.
It still feeds many of the same downstream programmes that drive EMT, stromal remodelling, invasion, and treatment escape.
Important overlap points include:
TGF-beta/SMAD signalling
YAP1/TAZ mechanosensing and matrix-stiffness responses
CTNNB1 / beta-catenin signalling
TWIST1 and VIM-linked mesenchymal shift
EZH2 and LSD1/KDM1A-linked epigenetic locking of resistant states
That overlap helps explain why FGFR1-amplified disease can also look biologically aligned with the same EMT and fibrosis nodes often discussed in resistant ER-positive disease.
This convergence is especially well described around TGF-beta, WNT, and YAP/TAZ, the YAP/TAZ fibrosis-cancer bridge, SMAD3-driven fibrotic signalling, and the broader biology of the fibrotic tumour stroma.
This page stays focused on ER-positive breast cancer.
For the broader cross-cancer framing of very hard, stiff, or “cement-like” lesions, including the three-layer model of driver programme, fibrotic scaffold, and fibrin/perfusion, see Fibrotic, Hard or “Cement‑Like” Lesions.
Adjuncts
No supplement has been shown to reliably erase FGFR1 amplification in patients.
Some options may have plausible downstream relevance to the FGFR1-EMT-fibrosis axis, but they are still experimental and supportive rather than proven FGFR1-directed treatments.
Losartan
Losartan as an anti‑fibrotic adjuvant
Losartan, an angiotensin II receptor blocker, has been studied as a way to remodel stiff, fibrotic tumour stroma by inhibiting TGF‑beta‑driven collagen deposition, reducing solid stress, and improving perfusion and drug delivery. This has been explored in preclinical and modelling work in breast and pancreatic cancer and fits into Layer 2 (fibrotic scaffold) and Layer 3 (perfusion) of the hard‑lesion picture. It does not target FGFR1 directly, but it may help soften some of the mechanical barriers that FGFR1‑driven biology builds.
Melatonin
Melatonin may affect endocrine signalling, oxidative stress, EMT, and some important FGFR-linked downstream pathways. That makes it mechanistically very interesting. It does not make it a proven treatment for FGFR1 amplification.
A recent paper by Doris Loh and colleagues proposes that melatonin may disrupt oncogenic phase separation by changing redox conditions, multivalent interactions, and intracellular electrochemical micro-environments.
In the 2026 paper by Loh et al., Multiaxial Biophysical Control of Oncogenic Phase Separation by Indoleamines, melatonin is discussed as a possible regulator of multiple condensate‑linked oncogenic hubs, including EMT and fibrotic drivers such as SMAD3, CTNNB1, YAP1/TAZ, TWIST1, VIM, EZH2, and LSD1/KDM1A, alongside other transcriptional and stress‑response nodes (for example EP300, SOX9, NANOG, TFEB, TFAM).
That overlaps conceptually with the same programmes often active in FGFR1-driven EMT and fibrosis biology.
It is not yet proof that melatonin directly targets FGFR1 amplification in patients.
For liposomal delivery context, see DIY Liposomal Melatonin in the Liposomal Encapsulation of Anti-cancer Compounds hub.
Key fibrotic condensate nodes in the 26-gene set
Several proteins in Loh’s condensate framework sit directly on the fibrosis and EMT axis.
SMAD3 is the clearest example.
It is a canonical TGF-beta effector in fibrosis.
It drives transcription of collagen, fibronectin, and other extracellular-matrix genes.
In Loh’s model, it also sits inside active nuclear hubs that help lock in fibrotic programmes.
TWIST1 is a core EMT factor.
It pushes cells toward a more mesenchymal, invasive, matrix-remodelling state, which fits the broader EMT-fibrosis overlap.
That makes it relevant to both metastatic escape and desmoplastic tumour behaviour.
VIM is more than a marker.
It supports the mechanics of mesenchymal transition and fibroblast-like cell behaviour in the same EMT-associated programme.
That matters in stiffer, more invasive, fibrosis-rich tumour settings.
YAP1 and TAZ are major mechanosensitive co-activators.
They help translate matrix stiffness into transcription.
That links them directly to CAF activation, tissue stiffening, and extracellular-matrix deposition, while Loh places them inside condensate-linked oncogenic hubs.
CTNNB1 or beta-catenin adds a second major fibrosis route.
It cooperates with TGF-beta and YAP/TAZ in EMT and fibroblast activation.
That makes it relevant where stromal remodelling and endocrine escape overlap.
EZH2 and KDM1A/LSD1 sit on the epigenetic side.
They help stabilise resistant and fibrogenic gene-expression states, and Loh includes them in Axis I condensate-linked control.
That matters if the question is not just signalling, but how a fibrotic programme becomes persistent.
EGFR is less fibrosis-specific on its own.
It still interacts with EMT-linked signalling networks in ways that can reinforce invasion and stromal activation.
Taken together, SMAD3, TWIST1, VIM, YAP1, TAZ, CTNNB1, EZH2, KDM1A, and EGFR are the main condensate-linked melatonin targets with the clearest overlap with fibrotic and desmoplastic biology.
How melatonin’s anti-fibrotic literature lines up with those targets
The broader melatonin literature lines up well with those same nodes.
Across organ-fibrosis and tumour-fibrosis models, melatonin repeatedly shows pressure against TGF-beta/SMAD3 signalling.
That usually means less SMAD3 activation, less nuclear fibrotic drive, and lower extracellular-matrix output.
Melatonin also repeatedly shows anti-EMT behaviour.
That includes pressure against factors such as TWIST1 and VIM, alongside preservation of more epithelial features.
That matters because EMT and fibrosis often travel together in resistant ER-positive disease.
The same logic extends to YAP/TAZ and beta-catenin.
The literature there is less tidy, but the direction is similar.
Melatonin often looks anti-mechanosensitive, anti-stiffness, and anti-remodelling.
The epigenetic layer also fits.
If melatonin lowers condensate stability around EZH2 and LSD1/KDM1A in Loh’s model, it could weaken the transcriptional memory that keeps fibrotic and resistant states locked in place.
That is still a research model.
It is not yet a validated clinical mechanism.
Even so, Loh’s framework gives a useful structural explanation for something the broader melatonin literature already suggests.
Melatonin may not need to target fibrosis through one single pathway.
It may instead destabilise several linked hubs at once around SMAD3, YAP/TAZ, beta-catenin, TWIST1, and related EMT-stromal programmes.
That same direction also fits breast-stromal data showing melatonin can reduce local estrogen-supportive signalling in breast-cancer-associated fibroblasts.
That is exactly the kind of overlap that makes melatonin biologically interesting in FGFR1-amplified, EMT-leaning, or fibrosis-rich ER-positive disease.
Honokiol
Honokiol is a biphenolic compound from Magnolia bark with preclinical anti‑cancer activity across several tumour types. In lung squamous cell carcinoma models, honokiol induced apoptosis, cell‑cycle arrest, and reduced migration while down‑regulating FGF2 and FGFR1 activation, and it suppressed growth of FGFR1‑driven xenografts by interrupting the FGF2–FGFR1 autocrine loop.
In breast‑cancer models, honokiol inhibits epithelial–mesenchymal transition, migration, and invasion via effects on Stat3/ZEB1/E‑cadherin signalling and EMT‑associated transcription factors, and it can sensitise breast‑cancer cells to TNF‑α‑induced apoptosis and leptin‑driven progression.
Human evidence specific to FGFR1‑amplified ER‑positive breast cancer is not established; honokiol should be considered an experimental adjunct with plausible relevance to FGFR1 signalling, EMT, and invasion based on preclinical work, not a validated targeted therapy in this setting.
Bottom line
FGFR1 amplification is a meaningful finding in ER-positive, HER2-negative breast cancer.
It most strongly points toward endocrine resistance pressure and more aggressive luminal-B-like biology.
If the signal fluctuates on Guardant360, the safest interpretation is usually changing ctDNA visibility, not proof that the biology was fake or permanently gone.
FGFR1 remains a real research target, but not a routine standard-of-care target in breast cancer today.
This page stays focused on the driver layer of FGFR in ER-positive breast cancer.
For the broader cross-cancer framing of very hard, stiff, or “cement-like” lesions, including the three-layer model of driver programme, fibrotic scaffold, and fibrin/perfusion, see Fibrotic, Hard or “Cement‑Like” Lesions.
Go to the ER+/HER2- Breast Cancer Hub Overview/Directory Page
Key references
FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6825550/Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1406951/fullFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC2832818/Association of FGFR1 with ERalpha Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer
https://aacrjournals.org/clincancerres/article/23/20/6138/80078/Association-of-FGFR1-with-ER-Maintains-LigandFuture perspectives: targeting fibroblast growth factor receptor 1 in cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC12179639/Pharmacological and Biological Targeting of FGFR1 in Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC11593329/FGFR1 Amplification — OncoKB
https://www.oncokb.org/gene/FGFR1/AmplificationThe Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrosis and Cancer
https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.607483/fullDwairy M et al., Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy — https://doi.org/10.1371/journal.pone.0328196
Return to the A–Z directory of
evidence-based research summaries and
practical support resources
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.